donepezil has been researched along with Hypotension in 2 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
Hypotension: Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Donepezil is a widely used cholinesterase inhibitor for the treatment of Alzheimer's disease (AD), however its cholinergic adverse side effects on the cardiovascular system are still unclear." | 6.77 | Cardiac safety of donepezil in elderly patients with Alzheimer disease. ( Aydemir, E; Bozoglu, E; Isik, AT; Yay, A; Yildiz, GB, 2012) |
| "Donepezil is a widely used cholinesterase inhibitor for the treatment of Alzheimer's disease (AD), however its cholinergic adverse side effects on the cardiovascular system are still unclear." | 2.77 | Cardiac safety of donepezil in elderly patients with Alzheimer disease. ( Aydemir, E; Bozoglu, E; Isik, AT; Yay, A; Yildiz, GB, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Isik, AT | 1 |
| Yildiz, GB | 1 |
| Bozoglu, E | 1 |
| Yay, A | 1 |
| Aydemir, E | 1 |
| Heller, JH | 1 |
| Spiridigliozzi, GA | 1 |
| Sullivan, JA | 1 |
| Doraiswamy, PM | 1 |
| Krishnan, RR | 1 |
| Kishnani, PS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 6 Months, Prospective, Open-label, Observational, Non-interventional Clinical Trial to Examine the Efficacy and Safety of Donepezil (Dementis®) Administration in Patients With Dementia.[NCT01772095] | 389 participants (Actual) | Observational | 2013-02-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for donepezil and Hypotension
| Article | Year |
|---|---|
Cardiac safety of donepezil in elderly patients with Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Arrhythmias, Cardiac; Blood Pressure; Cholinesterase Inh | 2012 |
Donepezil for the treatment of language deficits in adults with Down syndrome: a preliminary 24-week open trial.
Topics: Adult; Appetite; Cholinesterase Inhibitors; Diarrhea; Donepezil; Dose-Response Relationship, Drug; D | 2003 |